All articles
GLP-1 Side Effects: What's Normal, What's Not, and When to Get Help
Reading time:
15 min
Weight loss

Get expert guidance and a personalized care plan designed around you.
How Long Do Side Effects Last?
The timeline of side effects follows a predictable pattern for most people. The first two weeks are typically the most challenging. Nausea peaks, fatigue is most noticeable, and appetite changes feel most dramatic. This is the adjustment period when your body is learning to function with slower digestion and different hunger signals.
By weeks three and four, most people notice improvement. You develop strategies for managing remaining symptoms. Nausea becomes less intense or less frequent. Energy levels begin recovering. You start feeling more like yourself again, though with a substantially reduced appetite.
Between weeks five and eight, the majority of common side effects diminish significantly. Many people report feeling essentially normal again, though still experiencing the therapeutic effect of reduced appetite. This is the period when treatment starts feeling sustainable rather than challenging.
After each dose increase, you may experience a mini-return of side effects, usually milder than what you experienced initially. These typically last one to two weeks. Each subsequent dose increase tends to be easier than the previous one as your body becomes more adapted to the medication.
Long term, after three or more months on a stable dose, most people have minimal side effects. You may retain some sensitivity to large meals or high-fat foods, and reduced appetite becomes your new normal, but the disruptive symptoms of early treatment generally resolve.
Strategies for Minimizing Side Effects
There are practical steps you can take to reduce the intensity of side effects during the adjustment period.
Starting low and increasing slowly makes a substantial difference in tolerability. There is no benefit to reaching the maximum dose quickly. If side effects are significant, staying at each dose level for six weeks instead of four allows more time for adaptation. Work with your provider to find a titration schedule that balances effectiveness with tolerability.
Meal timing and composition matter more than you might expect. Eating smaller portions more frequently prevents overwhelming your slowed digestive system. Prioritizing protein at each meal supports muscle preservation and satiety. Avoiding high-fat, greasy, or fried foods during the adjustment phase reduces nausea for most people. Eating slowly and putting your utensil down between bites gives your body time to register fullness.
Hydration is one of the simplest and most effective ways to reduce side effects. Aim for at least 64 ounces of water daily, sipped throughout the day rather than consumed in large amounts at once. Many people find they need conscious effort to drink enough because thirst decreases along with appetite. Adequate hydration reduces constipation, fatigue, and headaches significantly.
Physical activity supports digestion and helps manage constipation, but it does not need to be intense. Daily walks, gentle yoga, or light strength training all provide benefits. During the first few weeks when fatigue may be higher, listen to your body and avoid pushing too hard. Movement should feel supportive, not exhausting.
Consider the timing of your injection. Some people do better injecting at night so they sleep through the peak symptom period. Others prefer morning injections. Experimenting with timing can help you find what works best for your schedule and symptom pattern.
Stock your kitchen with easy-to-digest foods before you start treatment. Having Greek yogurt, crackers, bananas, plain chicken, and protein shakes readily available makes it easier to eat well when appetite is low or nausea is present.
When to Contact Your Provider
Your provider wants to hear from you about your experience with GLP-1 therapy. Many people hesitate to reach out, assuming their symptoms are normal or not wanting to bother their provider. However, reporting side effects allows your provider to help you more effectively.
Contact your provider if nausea is severe enough to interfere with work or daily activities. They can prescribe anti-nausea medications or adjust your dose. If fatigue is limiting your ability to function normally, your provider may want to check labs or slow your dose increases. If constipation persists despite hydration and fiber, prescription options are available. If you are struggling to meet minimum nutritional needs, your provider or a dietitian can help you develop strategies.
Severe or persistent symptoms always warrant contact. Vomiting that prevents you from staying hydrated, severe abdominal pain, signs of dehydration, allergic reaction symptoms, or any of the red flag symptoms described earlier require prompt medical attention.
You should also reach out if you are considering stopping the medication due to side effects. In many cases, adjustments to dosing or additional support can make treatment tolerable. Stopping treatment should be a collaborative decision made with your provider's guidance.
What If One GLP-1 Medication Doesn't Work for You?
If you struggle significantly with one GLP-1 medication, you may tolerate a different one better. Semaglutide and tirzepatide have slightly different mechanisms and side effect profiles. Some people who cannot tolerate semaglutide do well with tirzepatide, and vice versa. Daily formulations like liraglutide also exist and may work better for some people.
Alternatively, some people do better on a lower maintenance dose long term rather than pushing to the maximum dose. Weight loss may be slower, but if the lower dose is sustainable and still producing results, that is a reasonable approach. Often, patients find they can maximize their progress at these lower dosages by incorporating specific daily habits that support the medication's effectiveness naturally.
The Bigger Picture
Side effects are a normal part of starting GLP-1 therapy for most people. They reflect your body's adjustment to changes in digestion and appetite signaling. While the first few weeks can be uncomfortable, the majority of side effects improve significantly with time and proactive management.
Understanding what is normal helps you navigate early treatment with less anxiety. Knowing warning signs helps you recognize when medical attention is needed. Having strategies for managing common symptoms makes the adjustment period more tolerable.
Most people find that side effects become much less of an issue after the first month or two. The medication becomes part of your routine, your body adapts, and the therapeutic benefits continue without the disruptive symptoms of early treatment. Patience, communication with your provider, and realistic expectations make all the difference in successfully navigating this process.
Check Your Eligibility
If you want to learn whether GLP-1 treatment is right for you and receive personalized guidance from providers who understand how to optimize your experience, you can start by completing Mochi's eligibility questionnaire. It only takes a few minutes and helps our clinical team understand your goals and health history. Check your eligibility here.
References:
Aroda, V. R., Ahmann, A., Cariou, B., Chow, F., Davies, M. J., Gigante, R., Nauck, M. A., Ørsted, D. D., Lingvay, I., & PIONEER 1 Investigators. (2019). Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the PIONEER trials. Diabetes Care, 42(9), 1595-1603. https://doi.org/10.2337/dc19-0149
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971-984. https://doi.org/10.1016/S0140-6736(21)00213-0
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022). Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: The SURPASS-5 randomized clinical trial. JAMA, 327(6), 534-545. https://doi.org/10.1001/jama.2022.0078
Drucker, D. J., & Nauck, M. A. (2006). The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet, 368(9548), 1696-1705. https://doi.org/10.1016/S0140-6736(06)69705-5
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. https://doi.org/10.1056/NEJMoa2206038
Meier, J. J. (2021). Efficacy of semaglutide in a subcutaneous and an oral formulation. Frontiers in Endocrinology, 12, 645617. https://doi.org/10.3389/fendo.2021.645617
Novo Nordisk. (2023). Ozempic (semaglutide) injection prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s014lbl.pdf
Novo Nordisk. (2023). Wegovy (semaglutide) injection prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s006lbl.pdf
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology, 6(4), 275-286. https://doi.org/10.1016/S2213-8587(18)30024-X
Rubino, D. M., Greenway, F. L., Khalid, U., O'Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., & Garvey, W. T. (2021). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA, 327(2), 138-150. https://doi.org/10.1001/jama.2021.23619
Sodhi, M., Rezaeianzadeh, R., Kezouh, A., & Etminan, M. (2023). Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA, 330(18), 1795-1797. https://doi.org/10.1001/jama.2023.19574
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://doi.org/10.1056/NEJMoa2032183
Eli Lilly and Company. (2023). Mounjaro (tirzepatide) injection prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215866s000lbl.pdf
Eli Lilly and Company. (2023). Zepbound (tirzepatide) injection prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
Share this post
Weight loss
More articles















